SINOTHERAPEUTICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.39 CNY | -3.10% |
|
-5.34% | -14.48% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 248M 34.3M 46.66M | Sales 2023 | 300M 41.54M 56.52M | Capitalization | 4.98B 690M 938M |
|---|---|---|---|---|---|
| Net income 2022 | 92M 12.75M 17.34M | Net income 2023 | 61M 8.45M 11.5M | EV / Sales 2022 | 27.6 x |
| Net cash position 2022 | 762M 106M 144M | Net cash position 2023 | 642M 88.9M 121M | EV / Sales 2023 | 14.5 x |
| P/E ratio 2022 |
76.1
x | P/E ratio 2023 |
84.5
x | Employees | 248 |
| Yield 2022 |
0.37% | Yield 2023 |
-
| Free-Float | 13.41% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.10% | ||
| 1 week | -5.34% | ||
| Current month | -0.95% | ||
| 1 month | +14.37% | ||
| 3 months | +29.16% | ||
| 6 months | -21.03% | ||
| Current year | -14.48% |
1 week
9.38
10.21
1 month
7.2710.27
Current year
6.3011.16
1 year
6.3015.68
3 years
6.3028.00
5 years
6.3028.00
10 years
6.3028.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Jie Guo
CEO | Chief Executive Officer | 51 | 23-04-05 |
Pei Hua Wei
DFI | Director of Finance/CFO | 48 | 12-05-31 |
Hui Zhang
BRD | Director/Board Member | 42 | 12-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Ye
CHM | Chairman | 51 | 12-07-31 |
Xiao Ming Ying
BRD | Director/Board Member | 56 | 12-07-31 |
Yong Lü
BRD | Director/Board Member | 67 | 20-08-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 9.39 | -3.10% | 1 985 790 |
| 24-05-14 | 9.69 | +0.73% | 2,245,292 |
| 24-05-13 | 9.62 | -1.33% | 2,661,606 |
| 24-05-10 | 9.75 | -1.81% | 3,773,556 |
| 24-05-09 | 9.93 | -1.49% | 4,071,370 |
End-of-day quote Shanghai S.E., May 14, 2024
More quotes
Sinotherapeutics Inc is China-based company mainly engaged in the research and development, commercial production and sales of pharmaceutical preparations. The Company's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The Company mainly operates in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.48% | 607M | |
| +21.28% | 44.4B | |
| +24.60% | 23.03B | |
| +19.22% | 15.14B | |
| +12.87% | 13.12B | |
| +44.67% | 11.85B | |
| -8.33% | 6.99B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.22% | 5.52B |
- Stock Market
- Equities
- 688247 Stock
